IV vs Subcutaneous amivantamab in EGFR NSCLC
Eric K. Singhi shared a post by Stephen V Liu, on X:
“Absolutely agree with this! Compared with IV amivantamab, subcutaneous delivery provides:
- non-inferior efficacy.
- low infusion-related reactions
- increased convenience (<5 minutes) This just makes sense for our patients!“
Quoting Stephen V Liu‘s post:
“Subcutaneous amivantamab Biologics License Application submitted to FDA. Based on PALOMA-3, this would clearly be my preferred route of administration once available.”
Read further.
Source: Eric K. Singhi/X and Stephen V Liu/X
Dr. Eric K. Singhi is a thoracic and head and neck medical oncologist, currently serving as an Assistant Professor in the Department of General Oncology within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX.
Dr. Singhi is highly skilled in general internal medicine and hematology/oncology, with a special focus on thoracic medical oncology. Dr. Eric K. Singhi is committed to delivering exceptional care to his patients and advancing the field of oncology.
Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.
His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.